Table 5.
Multivariable analysis evaluating the association between gene expression levels below each respective OOP and risk of presenting with organ failure/s adjusted for age, sex, Charlson comorbidity index, and CURB65.
| Age | Gender | Charlson Comorbidity Index | CURB65 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |
| Genes | ||||||||||
| HLA-DRA (<OOP) |
2.94 (1.07–8.09) | 0.037 | 1.01 (0.97–1.05) | 0.728 | 1.35 (0.48–3.79) | 0.565 | 1.41 (0.86–2.32) | 0.171 | 1.82 (0.98–3.39) | 0.058 |
| ICOS (<OOP) |
2.06 (0.76–5.58) | 0.154 | 1.01 (0.97–1.05) | 0.737 | 1.60 (0.59–4.34) | 0.355 | 1.48 (0.90–2.41) | 0.121 | 1.92 (1.04–3.54) | 0.038 |
| CD40LG (<OOP) |
3.90 (1.34–11.37) | 0.013 | 1.00 (0.96–1.04) | 0.924 | 1.54 (0.56–4.22) | 0.398 | 1.48 (0.90–2.43) | 0.120 | 1.91 (1.02–3.60) | 0.044 |
| CD3E (<OOP) |
2.42 (0.92–6.34) | 0.072 | 1.01 (0.97–1.05) | 0.766 | 1.61 (0.60–4.31) | 0.347 | 1.48 (0.91–2.41) | 0.119 | 1.96 (1.05–3.67) | 0.035 |
| CD28 (<OOP) |
3.48 (1.17–10.34) | 0.025 | 1.01 (0.97–1.05) | 0.777 | 1.52 (0.56–4.15) | 0.416 | 1.38 (0.84–2.27) | 0.210 | 1.86 (1.00–3.47) | 0.050 |
| Biomarkers | ||||||||||
| ProET1 (>OOP) |
6.50 (1.93–21.88) | 0.002 | 0.99 (0.95–1.04) | 0.750 | 0.80 (0.26–2.42) | 0.688 | 1.21 (0.71–2.05) | 0.490 | 1.45 (0.71–2.96) | 0.306 |
| ProADM (>OOP) |
2.42 (0.78–7.53) | 0.127 | 1.02 (0.97–1.06) | 0.566 | 0.84 (0.29–2.42) | 0.280 | 1.34 (0.79–2.26) | 0.746 | 1.23 (0.61–2.46) | 0.478 |
OR: odds ratio; CI: confidence interval; CURB65: confusion, urea, respiratory rate, blood pressure, 65 years; OOP: optimal operating point; ProET1: proendothelin-1; ProADM: proadrenomedullin; HLA-DRA: histocompatibility complex class II DR alpha; ICOS: Inducible T-cell costimulator; CD40LG: CD40 ligand.